Pharmaceutical Technology

MAY 11, 2023

Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.

RNA 345

RNA Vaccination Vaccine Trials 345

Bio Pharma Dive

MAY 24, 2022

began releasing supplies of an approved Bavarian Nordic shot, Moderna said it's beginning development of its own vaccine against the virus. One day after the U.S.

Vaccination 344

Vaccination Vaccine Development 344

Bio Pharma Dive

APRIL 23, 2021

A vaccine co-developed by the U.K. academic center and the Maryland biotech could be the first to meet the WHO's efficacy target for a malaria vaccine.

Vaccination 328

Vaccination Vaccine Development 328

Pharmaceutical Technology

AUGUST 5, 2024

Anivive Lifesciences has received the NIAID contract to develop a vaccine against coccidioides, the fungus responsible for valley fever.

Vaccination 235

Vaccination Vaccine Development 235

Pharmaceutical Technology

APRIL 19, 2023

The US Food and Drug Administration (FDA) has made changes to the emergency use authorisations (EUAs) of the Pfizer -BioNTech and Moderna bivalent mRNA Covid-19 vaccines. The latest amendment aims to simplify the vaccination schedule for most people. The changes mean that the current bivalent vaccines for the original and Omicron BA.4/BA.5

Vaccination 334

Vaccination Vaccine Gene Therapy Gene 334

Bio Pharma Dive

SEPTEMBER 17, 2020

The biotech, among the furthest along in coronavirus vaccine development, is the first developer to share the so-called study protocol of its large Phase 3 trial.

Vaccination 337

Vaccination Vaccine Trials Development 337

Pharmaceutical Technology

MAY 10, 2024

The FDA approved WestGene’s mRNA therapeutic cancer vaccine as mRNA cancer vaccine development rises in popularity.

FDA Approval 279

FDA Approval Vaccination Vaccine Development 279

Bio Pharma Dive

OCTOBER 12, 2022

The drugmaker’s decision to grab rights to the shot deepens its ties with the COVID-19 vaccine developer and comes weeks before a key data release.

Vaccination 317

Vaccination Vaccine Licensing Licensing 317

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccination 245

Vaccination Vaccine Development Allergies 245

Pharmaceutical Technology

NOVEMBER 25, 2022

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

Life Science 246

Life Science Vaccination Vaccine Development 246

Bio Pharma Dive

NOVEMBER 30, 2021

Philip Dormitzer, who helped Pfizer develop shots for COVID-19, RSV and influenza, will become the British pharma's head of vaccine R&D next month.

Vaccination 297

Vaccination Vaccine Scientist Development 297

Pharmaceutical Technology

MAY 30, 2023

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. The authorisation allows the distribution of the vaccine in Scotland, Wales and England.

Vaccination 298

Vaccination Vaccine Protein Medicine 298

Pharmaceutical Technology

AUGUST 3, 2023

AAHI is developing a novel RNA vaccine that overcomes manufacturing and storage limitations to increase accessibility.

RNA 244

RNA Vaccination Vaccine Development 244

Pharmaceutical Technology

DECEMBER 18, 2024

Abera and Orexo have entered a partnership to develop and test the powder formulations of the formers vaccine candidates.

Vaccination 264

Vaccination Vaccine Development 264

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Pharmaceutical Technology

APRIL 14, 2023

Ghana’s Food and Drug Authority (FDA) has approved R21/Matrix-M malaria vaccine in children aged 5 to 36 months, marking the first regulatory clearance for the University of Oxford-developed vaccine in any country in the world. Children between the ages of five and 36 months are at highest risk of death from malaria.

Vaccination 279

Vaccination Vaccine Manufacturing Containment 279

Pharmaceutical Technology

MARCH 14, 2023

The National Health Surveillance Agency (ANVISA) in Brazil has granted approval for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). The vaccine has received approval for preventing dengue disease in people aged four years to 60 years.

Vaccination 286

Vaccination Vaccine Clinical Trials Clinical Trials 286

Bio Pharma Dive

DECEMBER 13, 2022

The positive data are the most significant findings for the mRNA developer’s pipeline of experimental treatments outside of infectious diseases, where it has reaped billions from COVID-19 vaccine sales.

Vaccination 312

Vaccination Vaccine Sales Development 312

World of DTC Marketing

JANUARY 8, 2021

SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others. Can the FDA really control the quality of vaccine orders this big?

Vaccination 266

Vaccination Vaccine Pharma Companies Development 266

Bio Pharma Dive

APRIL 1, 2021

Updated Phase 3 study results could position Pfizer to file for full approval of its vaccine and might have implications for its plans to develop a booster shot.

Vaccination 306

Vaccination Vaccine Development 306

Pharmaceutical Technology

AUGUST 17, 2022

On August 8, Pfizer and Valneva announced the initiation of a Phase III study with their Lyme disease vaccine , bringing the prospect of an injection to prevent the condition disease one step closer to reality. This means that the vaccine works against multiple serotypes of the disease, she explains. A one-size-fits-all approach.

Vaccination 299

Vaccination Vaccine Bacteria Protein 299

Bio Pharma Dive

APRIL 1, 2024

The development of cancer vaccines has provided some hope in the battle against cancer worldwide; however, there are still many challenges to overcome when developing these life-saving treatments.

Vaccination 258

Vaccination Vaccine Development 258

Pharmaceutical Technology

SEPTEMBER 7, 2022

Indian company Bharat Biotech International has secured approval from Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for its intranasal Covid-19 vaccine, iNCOVACC (BBV154), for usage in people aged 18 years and older. It is formulated to permit intranasal delivery via nasal drops.

Vaccination 263

Vaccination Vaccine Clinical Trials Clinical Trials 263

Bio Pharma Dive

SEPTEMBER 8, 2020

In an unusual letter, the heads of nine top vaccine developers pledged to "stand with science" and only move forward with approval applications if warranted by clinical results.

Vaccination 299

Vaccination Vaccine Development 299

Bio Pharma Dive

MAY 9, 2022

The companies' hepatitis B program never reached clinical testing, while J&J said it would no longer develop an HPV vaccine because of the "widespread uptake" of effective shots from other companies.

Vaccination 300

Vaccination Vaccine Development 300

Pharmaceutical Technology

MAY 9, 2024

Anixa Biosciences has expanded its partnership with Cleveland Clinic to develop additional vaccines for cancers.

Vaccination 246

Vaccination Vaccine Development 246

Bio Pharma Dive

JULY 5, 2022

The biotech, whose own efforts to develop a COVID-19 vaccine have faltered, claims its inventions were crucial to the development of BioNTech’s top-selling coronavirus shot.

Vaccination 286

Vaccination Vaccine Development 286

Pharmaceutical Technology

SEPTEMBER 21, 2023

The collaboration will use Evaxion’s EDEN platform to bring an AI-designed gonorrhea mRNA vaccine to the market.

Vaccination 246

Vaccination Vaccine Development Marketing 246

Pharmaceutical Technology

FEBRUARY 7, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]). The vaccine candidate has been approved for active immunisation against the infection in people from four years of age.

Vaccination 264

Vaccination Vaccine Genetics Trials 264

Bio Pharma Dive

AUGUST 11, 2020

The shot, developed by the state-backed Gamaleya Research Institute, hasn't yet been tested in the large, placebo-controlled tests scientists emphasize are needed to prove a vaccine is protective.

Vaccination 277

Vaccination Vaccine Scientist Development 277

Pharmaceutical Technology

AUGUST 1, 2022

Moderna has entered a new supply contract with the US Government to deliver 66 million doses of its Covid-19 vaccine booster candidate, mRNA-1273.222. The contract comprises a $1.74bn award to produce and supply these vaccine doses and options to further procure up to 234 million additional doses of the company’s booster candidates.

Vaccination 289

Vaccination Vaccine Gene Therapy RNA 289

Bio Pharma Dive

JULY 7, 2021

Having proved mRNA's might in COVID-19, the biotech company aims to develop similar vaccines for other respiratory illnesses caused by influenza, RSV and metapneumovirus.

Vaccination 278

Vaccination Vaccine Development 278

Bio Pharma Dive

OCTOBER 13, 2023

The awards, to biotechs Gritstone, Codagenix and CastleVax, are part of the program’s plan to develop vaccines with broader or longer-lasting benefits.

Vaccination 282

Vaccination Vaccine Development 282

Bio Pharma Dive

SEPTEMBER 28, 2020

The FDA has suspended the planned start of a late-stage trial of Inovio's experimental shot, dealing another setback to one of the most advanced DNA-based vaccine programs in development.

Vaccination 269

Vaccination Vaccine DNA Trials 269

Pharmaceutical Technology

MAY 2, 2023

4/5 Covid-19 messenger RNA (mRNA) vaccines. The expanded EUAs state that these current bivalent vaccines are now to be used for all primary and booster doses administered to individuals ages six months of age and older. 1 vaccines by both companies were revoked by the FDA in August 2022, after the BA.5

Vaccination 52

Vaccination Vaccine RNA Development 52

Pharmaceutical Technology

JULY 1, 2022

Some months after the first Covid-19 vaccines became available, the World Health Organization (WHO) set a target of vaccinating 70% of each country’s population by the end of June 2022. The post Magazine-How delays derailed Covid-19 vaccination in Africa appeared first on Pharmaceutical Technology.

Vaccination 277

Vaccination Vaccine Big Data Development 277